InvestorsHub Logo
Followers 646
Posts 144549
Boards Moderated 1
Alias Born 05/19/2007

Re: None

Wednesday, 03/24/2021 9:11:00 AM

Wednesday, March 24, 2021 9:11:00 AM

Post# of 640601
$NBIO announced today that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

Screening to enroll patients in the trial is already underway. Those interested may review trial requirements h ere .

PTB is a natural human antibody that works by binding to Cell surface Vimentin (sometimes referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.

"Because EDV is found in a variety of cancers, our important clinical trials involving PTB could have implications for a broad range of more common cancers, such as breast, colon and lung," noted Nascent CEO, Sean Carrick. "The current Phase 1 trial has been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors."

https://finance.yahoo.com/news/nascent-biotech-opens-phase-1-120000666.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.